12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Status:
Terminated
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of
12-O-tetradecanoylphorbol-13-acetate in treating patients with hematologic cancer or bone
marrow disorder that has not responded to previous treatment.
Phase:
Phase 1
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey